TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00908986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 q week x 4; repeated in 6 months
Study: NCT05461859

Intervention type: PROCEDURE
Intervention: Cardioneuroablation (CNA) of the right anterior ganglionated plexus (RAGP)
Description: CNA of RAGP

Intervention type: PROCEDURE
Intervention: Cardioneuroablation (CNA) of the right anterior ganglionated plexus (RAGP)
Description: CNA of RAGP
Study: NCT02649413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Children with Idiopathic Nephrotic syndrome will start 60 mg/m2 prednisone.children that response in 8 days will receive an adjusted dose while the rest of the group will receive the 4 weeks usually dose.
Study: NCT05400135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qungasvik (Tools for Life)
Description: The Qungasvik (toolbox) intervention is designed to build protection against alcohol use disorder (AUD) and suicide in Yup'ik Alaska Native youth 12-18 years old. The intervention is a community-driven and culturally-based process that develops and delivers 18-24 prevention activities leading to the two primary prevention variables, Reasons for Life and Reflective Processes about the Consequences of Alcohol Use and secondary prevention variables of multi-level protective factors and social networks.
Study: NCT02361385

Intervention type: OTHER
Intervention: this is not an interventional study
Description: this is not an interventional study; this is a pilot feasibility study to see whether or not 11CPR28 will be taken up in joints of those known to have active arthritis clinically
Study: NCT03084146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-week elimination diet
Description: individualized 12-week elimination diet based on the 4 most reactive foods +/- a gluten-free diet if there is detection of positive anti- tissue transglutaminase (tTG) IgG and IgA and anti-deamidated gliadin peptide (DGP) IgG and IgA
Study: NCT00984256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone Proguanil
Description: Volunteers will receive doses of atovaquone/proguanil (Malarone) or matching sugar pills.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Procedure - malaria challenge
Description: 2) Procedure- Malaria Challenge- Volunteers will be exposed to bites of infectious mosquitoes with the intention of causing malaria infection. Volunteers infected with malaria will undergo approved treatments for malaria.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procedure - malaria challenge
Description: 2) Procedure- Malaria Challenge- Volunteers will be exposed to bites of infectious mosquitoes with the intention of causing malaria infection. Volunteers infected with malaria will undergo approved treatments for malaria.
Study: NCT03737123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 4 IV Day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1,000 mg/m2 IV Day 1 and Day 8 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1,200 mg IV Day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 IV Day 1 of each 21 day Cycle.
Study: NCT04931940

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients will receive the usual protein dosage at ≤1.2 g/kg/day for up to 28 days in the ICU

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Higher Protein/Amino Acid Group
Description: Patients will receive high protein dosage at ≥2.2 g/kg/day for up to 28 days in the ICU
Study: NCT00445549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: 300 mg daily dose, 28 day cycle
Study: NCT01572207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate exercise
Description: Subjects in the immediate exercise group will be prescribed a home exercise program during the first meeting and will begin the 12 week training period immediately following the first meeting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed exercise
Description: Subjects in the delayed exercise group will begin the home exercise program 12 weeks following the initial meeting.
Study: NCT03078114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: The subject will be asked to lay down and bend in a specific way. The clinician will apply force to certain areas to manipulate the spine.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Spinal Manipulation
Description: The subject will be asked to lay down and bend in a specific way. The clinician will apply force to certain areas to simulate manipulating the spine.
Study: NCT01925560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agave Inulin
Description: 3x3 Latin square with 3 periods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agave Inulin
Description: 3x3 Latin square with 3 periods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agave Inulin
Description: 3x3 Latin square with 3 periods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: control- 0 (zero) grams/day inulin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: control- 0 (zero) grams/day inulin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: control- 0 (zero) grams/day inulin
Study: NCT02669953

Intervention type: DRUG
Intervention: Aflibercept

Intervention type: DRUG
Intervention: Aflibercept

Intervention type: DRUG
Intervention: Aflibercept

Intervention type: DRUG
Intervention: Aflibercept
Study: NCT04416204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glycogen loading
Description: Subjects will consume an isocaloric diet \[60% carbs, 20% protein, 20% fat (33 kcal/kg/day)\] for 3 days prior to the overnight study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glycogen loading
Description: Subjects will consume an isocaloric diet \[60% carbs, 20% protein, 20% fat (33 kcal/kg/day)\] for 3 days prior to the overnight study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Glycogen Loading
Description: Subjects will consume an isocaloric diet \[40% carbs, 20% protein, 40% fat (33 kcal/kg/day)\] for 3 days prior to the overnight study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Glycogen Loading
Description: Subjects will consume an isocaloric diet \[40% carbs, 20% protein, 40% fat (33 kcal/kg/day)\] for 3 days prior to the overnight study.
Study: NCT04545229

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR-based Pain Alleviation Tool (VR-PAT)
Description: Four smart phone based virtual reality games developed by the Research Information Solutions and Innovation (RISI) at the Nationwide Children's Hospital.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR-based Pain Alleviation Tool (VR-PAT)
Description: Four smart phone based virtual reality games developed by the Research Information Solutions and Innovation (RISI) at the Nationwide Children's Hospital.
Study: NCT03602612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on day -5, -4, -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on day -5, -4, -3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells
Description: 0.75x10\^6 - 12.0X10\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells
Description: 0.75x10\^6 - 12.0X10\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
Study: NCT03080857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Platform
Description: The platform will direct patients to review the Canadian Cardiovascular Guidelines and the Heart \& Stroke website for commonly asked questions relating to atrial fibrillation, as well as recommendations regarding nutrition and activity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AliveCor Heart Monitor
Description: A substudy of patients enrolled into the CSAF Tool study who own a compatible smart phone will be randomized to the Alive Cor Heart Monitor plus the virtual platform versus the virtual platform alone. The purpose of this substudy is to assess the feasibility and effect of incorporating Alive COR into a virtual online patient-education platform on patients' quality of life and AF-related emergency room visits and hospitalizations.
Study: NCT00675181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: 5mg per os

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: per os
Study: NCT04846829

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline PBO will be administered intravenously using established clinical procedures. A single dose if saline PBO will be delivered intravenously under double-blind conditions via pump over a 40-minute period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation
Description: 10 sessions of treatment with cTBS to right DLPFC TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).~iTBS paradigm of a 2 s train repeated every 10 seconds

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous citalopram hydrochloride (CIT)
Description: CIT will be administered intravenously using established clinical procedures. A single 40 mg dose of CIT diluted in 60 cc normal saline will be delivered intravenously under double-blind conditions via pump over a 40-minute period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation
Description: 10 sessions of treatment with iTBS to left or cTBS to right DLPFC TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).~1800 pulses of cTBS will be delivered
Study: NCT02592031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XM17
Description: 300 IU corresponds to an injection volume of 0.5 mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonal-f®
Description: 300 IU corresponds to an injection volume of 0.5 mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoladex®
Description: 3.6 mg
Study: NCT01364896

Intervention type: PROCEDURE
Intervention: Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samples
Description: Before and at least 6 months after starting a new non-steroid immunosuppressive agent for IBD treatment, eligible participants who are attending for routine colonoscopy will have:~1. Anal swab samples (and vaginal swab samples for female participants) for human papillomavirus PCR typing (6, 11, 16, 18, 31, 33, 45, 52, 58)~2. High-resolution anoscopy and biopsy of all visible high-grade dysplastic lesions based on validated colposcopic criteria~3. Anal cytology testing
Study: NCT02153593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 1g intra-articular before closing the wound surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Description: 5mL intra-articular before closing the wound surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocauterization
Description: Coagulation blood from vessels by means of a electrocautery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocauterization
Description: Coagulation blood from vessels by means of a electrocautery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocauterization
Description: Coagulation blood from vessels by means of a electrocautery
Study: NCT01393158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: 20mg of Apremilast taken orally BID for 3 months or 30 mg of Apremilast taken orally BID for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: 20mg of Apremilast taken orally BID for 3 months or 30 mg of Apremilast taken orally BID for 6 months.
Study: NCT00924521

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole grain diet
Description: Participants in this group will receive 6-9 servings of whole grain daily to replace the refined grains typically included in the average American diet. Number of servings will depend upon calorie assignment.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Refined grain
Description: Participants in this group will receive only refined grains as typically consumed in the average American diet.
Study: NCT02324881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Use PSMA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02547311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team Clinic
Study: NCT04233801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02113696

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 intake, morbid obesity
Description: Individuals of both sexes with ages between 18 and 65 years took 3g of omega 3, and 1.8g eicosapentaenoic acid (EPA) and 1.2g docosahexanoic acid (DHA) for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo Capsules
Description: They received gelatin (colorless) capsules. A nutritional evaluation was performed, a 24-h recordatory was applied to verify macro and micronutrients intake, biochemical evaluation before and after the intervention. Macro and micronutrients were calculated using the Avanutri 2.0 system. Clinical history was verified through a questionnaire previously filled out by a physician.
Study: NCT03272802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone
Description: Edaravone is a free radical scavenger. this drug showed desirable effects like slowing decline of physical function by 33 percent in previous studies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Riluzole is a treatment option for amyotrophic lateral sclerosis. The occurrence of ventilator-dependence or tracheostomy is delayed in selected patients who treated with this drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riluzole
Description: Riluzole is a treatment option for amyotrophic lateral sclerosis. The occurrence of ventilator-dependence or tracheostomy is delayed in selected patients who treated with this drug.
Study: NCT02755428

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: retinal pigment epithelium transplantation
Description: Transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
Study: NCT02421172

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CJM112
Description: CJM112 Fully human IgG1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CJM112
Description: CJM112 Fully human IgG1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CJM112
Description: CJM112 Fully human IgG1 monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01366768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral amino acid mixture
Description: Amino acid mixture 2,93 ml/kg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous amino acid administration
Description: Amino acid mixture 2,93 ml/kg
Study: NCT01841281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Arginine
Description: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Arginine
Description: L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.
Study: NCT04058938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational handout instrument
Description: The handout was single-paged (front and back), and was titled Pain After Surgery: What to Expect. The handout starts with information on rating pain and expectations for control of pain, not complete absence of pain, after surgery. Mutli-modal approach to pain control is then discussed, including pharmacologic and non-pharmacologic methods that may be used for pain control by the perioperative team and postoperatively.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard patient counseling
Study: NCT03112681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar magnesium 2 mg
Description: Saroglitazar magnesium 2 mg once daily in the morning before breakfast without food, for a period of 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar magnesium 4 mg
Description: Saroglitazar magnesium 4 mg once daily in the morning before breakfast without food, for a period of 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo once daily in the morning before breakfast without food, for a period of 16 weeks.
Study: NCT00558142

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcysteine
Description: Participants will receive packs of either 8 placebo capsules or 8 acetylcysteine (600mg) capsules. They will be asked to take 2 tablets at 08.00 and 22.00 on the day before the study and the day of the study. On the day of the study participants will receive an IV infusion of either normal saline or acetylcysteine (200mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcysteine
Description: Participants will receive packs of either 8 placebo capsules or 8 acetylcysteine (600mg) capsules. They will be asked to take 2 tablets at 08.00 and 22.00 on the day before the study and the day of the study. On the day of the study participants will receive an IV infusion of either normal saline or acetylcysteine (200mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcysteine
Description: Participants will receive packs of either 8 placebo capsules or 8 acetylcysteine (600mg) capsules. They will be asked to take 2 tablets at 08.00 and 22.00 on the day before the study and the day of the study. On the day of the study participants will receive an IV infusion of either normal saline or acetylcysteine (200mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcysteine
Description: Participants will receive packs of either 8 placebo capsules or 8 acetylcysteine (600mg) capsules. They will be asked to take 2 tablets at 08.00 and 22.00 on the day before the study and the day of the study. On the day of the study participants will receive an IV infusion of either normal saline or acetylcysteine (200mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Visipaque 320
Description: 100mls IV dose as single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Visipaque 320
Description: The dose of Visipaque will be administered by the consultant cardiologist performing the coronary angiography
Study: NCT04126681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HQP1351
Description: HQP1351 is a new, bioavailable inhibitor against BCRABLWT and a broad spectrum of BCR-ABL mutants including BCR-ABLT315I

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea or Interferon-based therapy
Description: Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Homoharringtonine
Description: Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib, Dasatinib or Nilotinib
Description: Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
Study: NCT02206204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selexipag

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for selexipag
Study: NCT00599872

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Ragweed Allergenic Extract
Description: Standardized Ragweed Allergenic Extract, sublingual oral

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, sublingual oral
Study: NCT04013386

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant and Dexamethasone
Description: Aprepitant capsule 80 mg and Dexamethasone 8 mg IVI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine and Dexamethasone
Description: Mirtazapine tablet 30 mg and Dexamethasone 8 mg IVI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 8 mg IVI
Study: NCT01343953

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord Blood Transplantation
Description: One or 2 cord blood units containing alone or both together more than 4x107 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the patients for acquired Severe Aplastic Anemia